Grandi Vieri, Colantuono Virginia Alba, Pimpinelli Nicola
Dermatology Unit, Department of Health Sciences, University of Florence Medical School, Florence; Melanoma and Skin Cancer Unit, Central Tuscany Health District, Italy.
Dermatol Reports. 2024 May 7;16(Suppl 2):9926. doi: 10.4081/dr.2024.9926.
The most common and widespread type of cutaneous T-cell lymphoma is mycosis fungoides (MF), and it has a multiphasic clinical and biological course, with early stages being indolent for many years and later stages being faster and more aggressive. The clinical stage has a significant impact on the management and course of treatment: in the early stages, skin-directed therapies (SDT) plus/or biologic response modifiers (BRM); in the later stages, radiotherapy and/or systemic therapies. Even though national and international societies and groups periodically update their clinical recommendations, there is still no universally accepted approach. This paper reviews and discusses the various SDT and BRM options, either separately or in combination.
蕈样肉芽肿（MF）是最常见且分布最广泛的皮肤T细胞淋巴瘤类型，它具有多阶段的临床和生物学病程，早期阶段多年进展缓慢，后期阶段进展更快且更具侵袭性。临床分期对治疗管理和疗程有重大影响：在早期，采用皮肤定向治疗（SDT）加和/或生物反应调节剂（BRM）；在后期，采用放射治疗和/或全身治疗。尽管国家和国际协会及团体定期更新其临床建议，但仍没有普遍接受的方法。本文回顾并讨论了各种单独或联合使用的SDT和BRM选项。
